# A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

> **NCT03083665** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 449 (actual)

## Conditions studied

- Partial Seizures With or Without Secondary Generalization
- Epilepsy

## Interventions

- **DRUG:** Placebo
- **DRUG:** Brivaracetam

## Key facts

- **NCT ID:** NCT03083665
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-22
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 449 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03083665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03083665, "A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03083665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*